Reflux symptoms in patients with achalasia.

Reflux symptoms in patients with achalasia. - Reflux symptoms in achalasia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37315

Enrollment

Registered

2013-01-30

Start date

2013-03-18

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achalasia Oesophageal motility disorder

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Treated achalasia patients WITH gastroesophageal reflux symptoms 1) Diagnosis of idiopathic achalasia confirmed by esophageal manometry that shows the following criteria: - Aperistalsis or simultaneous contractions in the esophageal body. - LES dysrelaxation. 2) Treatment of achalasia with one of the following procedures: - Endoscopic balloon dilatation - Surgical Heller myotomy - Per-oral endoscopic myotomy (POEM) 3) Minimum total score on the GastroEsophageal Reflux Disease Questionnaire (GERDQ) of * 8. 4) Gastroesophageal symptoms after treatment lasting more than 3 months. 5) Age 18-80 years. 6) Written informed consent.;Treated achalasia patients WITHOUT gastroesophageal reflux symptoms 1) Diagnosis of idiopathic achalasia confirmed by esophageal manometry that shows the following criteria: - Aperistalsis or simultaneous contractions in the esophageal body. - LES dysrelaxation. 2) Treatment of achalasia with one of the following procedures: - Endoscopic balloon dilatation - Surgical Heller myotomy - Per-oral endoscopic myotomy (POEM) 3) Maximum total score on the GastroEsophageal Reflux Disease Questionnaire (GERDQ) of

Exclusion criteria

Exclusion criteria: Treated achalasia patients WITH gastroesophageal reflux symptoms - Pseudoachalasia. - Upper gastrointestinal malignancy. - Chagas disease. - Peptic ulcer disease. - Inability to stop PPI, H2-receptor antagonist or prokinetic drug for two weeks. - Presence of an extremely dilated oesophagus body >5 cm.;Treated achalasia patients WITHOUT gastroesophageal reflux symptoms - Pseudoachalasia. - Upper gastrointestinal malignancy. - Chagas disease. - Peptic ulcer disease. - Inability to stop PPI, H2-receptor antagonist or prokinetic drug for two weeks. - Presence of an extremely dilated oesophagus body >5 cm.

Design outcomes

Primary

Measure	Time frame
Gastroesophageal reflux episodes.	—

Secondary

Measure	Time frame
LES pressure. Esophagogastric junction distensibility. Sensitivity to acid perfusion and distension. Level of esophageal stasis. Widt/diameter of the esophagus.	—

Countries

Netherlands

Outcome results